| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 100‐115 mm Hg at both week 3 and week 4 run‐in visits, with at least 4 days between the two visits and a difference of 7 mm Hg or less between two DBP measurements; 8‐week double‐blind treatment |
| Participants |
Olmesartan 10 mg: n=39(24 males,15 females); mean age=49.9(10.9) years; baseline sitting SBP=153.6 mm Hg, DBP=104.1 mm Hg;
Olmesartan 20 mg: n=41(21 males,20 females); mean age=54.1(9.9) years; baseline sitting SBP=154.6 mm Hg, DBP=103.2 mm Hg;
Olmesartan 40 mg: n=45(28 males,17 females); mean age=54.4(11.2) years; baseline sitting SBP=152.9 mm Hg, DBP=102.6 mm Hg;
Placebo: n=42(27 males,15 females); mean age=54.0(9.9) years; baseline sitting SBP=152.1 mm Hg, DBP=103.4 mm Hg |
| Interventions |
Olmesartan 10 mg once daily;
Olmesartan 20 mg once daily;
Olmesartan 40 mg once daily;
Placebo;
taken in the morning with breakfast |
| Outcomes |
Trough sitting SBP/DBP |
| Notes |
BP and SD of change not reported, endpoint BP reported, endpoint SD not reported, baseline SD not reported; imputed overall trial mean SBP/DBP SD of change; BP data from Table 2, p. 256; BP measurement device not reported; Jadad score=2; funding source= Sankyo Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
